Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search
		×
			Vaccines site
			Vaccines site
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


Advisory Committee on Immunization Practices (ACIP)


Section Navigation
			
			CDC Home








ACIP Work Groups						Print
																Related Pages
										ACIP uses subgroups of the Committee, known as Work Groups, to review relevant published and unpublished data and develop recommendation options for presentation to the ACIP. The goal of ACIP Work Groups is to increase the effectiveness of ACIP.
ACIP Work Groups are responsible for collection, analysis, and preparation of information for presentation, discussion, deliberation, and vote by the ACIP in an open public forum. Work Groups review specific topics in detail and clarify issues in a way that helps ACIP voting members make informed and efficient decisions, with the best and most current information available.
The following Work Groups are currently active (click on the name of each Work Group for more information): (Updated 11/29/2022)
Combined Child/Adolescent and Adult Immunization Schedules
Influenza Vaccines
Chikungunya Vaccines
COVID-19 Vaccines
Meningococcal Vaccines
Pneumococcal Vaccines
Polio Vaccines
Respiratory Syncytial Virus Vaccines – Pediatric/Maternal
Respiratory Syncytial Virus Vaccines – AdultCombined Child/Adolescent and Adult Immunization Schedule
Work Group Purpose: The Combined Child/Adolescent and Adult Immunization Schedule Work Group edits and maintains the annual child/adolescent and adult immunization schedule documents. The child/adolescent immunization schedule summarizes the ACIP vaccination recommendations for persons 18 years of age and younger, and the adult immunization schedule summarizes the ACIP vaccination recommendations for persons 19 years of age and older.
Topics under discussion by the Work Group: The products of this work group do not establish new vaccine recommendations; the work group documents reflect existing ACIP recommendations.
Work Group activities:
Publication of the annual child/adolescent and adult immunization schedules
Work Group Co-Leads: Patricia Wodi and Neil Murthy
Work Group Chair: Sybil CineasTop of PageInfluenza Vaccines
Work Group Purpose: The Influenza Vaccine Work Group discusses the annual seasonal influenza vaccination recommendations and develops policy options for ACIP’s consideration. The Work Group reviews data and literature related to influenza vaccine efficacy, effectiveness, and safety.  Data concerning new licensures and licensure changes are also discussed.
Topics under discussion by the Work Group:
Assessment of specific influenza vaccines in specific populations (e.g., based upon age, risk factors for severe illness, susceptibility to adverse events)
Timing of vaccination
Vaccination during pregnancy
Evidence assessment and policy development for new vaccines
Effectiveness and safety of different influenza vaccines relative to one another
Work Group activities:
Ongoing discussions of vaccine effectiveness (VE)
Ongoing discussions of vaccine safety
Discussion of new licensures and licensure changes as relevant
Work Group Lead: Lisa Grohskopf
Work Group Chair: Keipp TalbotTop of PageChikungunya Vaccines
Work Group Purpose: The Chikungunya Vaccines Work Group reviews and evaluates data on chikungunya disease, epidemiology, and vaccines and develops policy options for ACIP’s consideration.
Topics under discussion by the Work Group:
Use of chikungunya vaccine in U.S. persons at risk of chikungunya, including those who travel abroad and residents of U.S. territories and states with, or at risk of, transmission.
Work Group activities:
Review information on chikungunya disease, including outcomes
Review data on chikungunya epidemiology and burden among U.S. residents, including travelers and persons living in areas at risk for local transmission
Review data on safety, immunogenicity, and effectiveness of chikungunya vaccines
Provide evidence-based recommendation options for ACIP
Identify areas in need of further research for informing potential future vaccine recommendations
Publish chikungunya vaccine MMWR Recommendations and Reports document
Work Group Lead: Susan Hills
Work Group Chair: Beth BellTop of PageCOVID-19 Vaccines
Work group purpose: To review available data to inform COVID-19 vaccine policy, including recommendations for use of COVID-19 vaccines in the US population.
Topics under discussion by the work group:
Use of COVID-19 vaccines in the U.S. population
Work group activities:
Review safety, efficacy and immunogenicity data for COVID-19 vaccines, particularly in vaccine candidates authorized, approved, or in clinical trials in the US.
Review the epidemiology of COVID-19 disease
Assess benefit-risk balance for use of COVID-19 vaccines
Identify areas where additional data are needed to inform COVID-19 vaccine recommendations
Develop COVID-19 vaccine policy options
Work Group Co-Leads: Megan Wallace and Lakshmi Panagiotakopoulos
Work Group Chair: Matthew DaleyTop of PageMeningococcal Vaccines
Work Group Purpose: Meningococcal disease is a rare but serious bacterial infection. Currently, licensed vaccine products are available in the United States for protection against the primary disease-causing serogroups: serogroup A, C, W, Y conjugate (MenACWY) and serogroup B (MenB) vaccines. The purpose of the ACIP meningococcal vaccines work group is to review data on meningococcal vaccines and develop meningococcal vaccine policy options for ACIP consideration.
Topics under discussion by the Work Group:Incorporation of the new Menveo liquid formulation into the current Menveo recommendations.
Use of pentavalent (MenABCWY) vaccines in the United States.
Evaluate use of meningococcal vaccines for persons experiencing homelessness.Work Group activities:Review available safety, immunogenicity, persistence of antibody protection, and effectiveness data for MenB, MenACWY, and MenABCWY vaccines.
Review the epidemiology of meningococcal disease and potential impact of vaccination in targeted populations.
Identify areas in need of further evaluation to inform future work group deliberations.Work Group Co-Leads: Jennifer Collins and Lucy McNamara
Work Group Chair: Katherine PoehlingTop of PagePneumococcal Vaccines
Work Group Purpose: Each year in the United States, pneumococcal disease causes thousands of infections, such as meningitis, bloodstream infections, pneumonia, and ear infections. The Pneumococcal Vaccines Work Group:
Reviews current data on pneumococcal disease burden, and on the efficacy, effectiveness, immunogenicity, and cost-effectiveness of pneumococcal vaccines and assesses the strength of the evidence;
Reviews current pneumococcal vaccine recommendations considering up-to-date evidence; and
Develops revised or updated policy options for pneumococcal vaccines as needed.
Topics under discussion by the Work Group:
Use of new pneumococcal conjugate vaccines in U.S. adults and children.
Work Group activities:
Review new evidence for PCV15 and PCV20 use among adults
Review evidence for PCV20 use among children
Finalize Evidence to Recommendations framework including GRADE
Update MMWR Policy Note and MMWR Recommendation and Report, as needed
Work Group Lead: Miwako Kobayashi
Work Group Chair: Katherine PoehlingTop of PagePolio Vaccines
Work Group Purpose: Due to the recent occurrence of a case of paralytic polio in New York, circulation of vaccine derived polioviruses in numerous countries (cVDPVs), and advances in vaccine development, an ACIP Polio Work Group is being reestablished. In addition, the current ACIP statement on Poliomyelitis Prevention in the United States was published in 2000 and should be updated.
Topics under discussion by the Work Group:
Whether more specific guidance on polio vaccination for adults, including use of adult booster doses, can be provided in the context of circulating poliovirus.
Whether adults who are immunocompromised should be recommended an additional adult booster of a polio-containing vaccine.
Whether fractional doses of inactivated polio vaccine (fIPV), as prequalified by WHO, should meet vaccination requirements, including for people immigrating to the United States
Consider criteria under which novel oral polio vaccine (nOPV) might be used in areas with outbreaks or persistent circulation of poliovirus.
Work Group activities:
Review safety and immunogenicity data for IPV
Review safety and immunogenicity data for fIPV
Review serosurvey data to understand duration of humoral immunity among adults with differing vaccine histories (OPV, OPV/IPV, IPV)
Review safety and immunogenicity data for nOPV
Review data on immunogenicity and efficacy or effectiveness among vaccinated immunocompromised adults vaccinated as children
Review data on immunogenicity of IPV administered to immunocompromised adults
Consider under what epidemiologic conditions nOPV might be used, if licensed by FDA
Work Group Lead: Sarah Kidd
Work Group Chair: Oliver BrooksTop of PageRespiratory Syncytial Virus Vaccines – Pediatric/Maternal
Work Group Purpose: Respiratory syncytial virus (RSV) is a major cause of lower respiratory illness, particularly among infants and children and among older adults and adults with chronic medical conditions. RSV vaccine and immune globulin development has progressed in the past decade with over 40 candidate vaccines and monoclonal antibodies currently in development.  Target populations for whom these products are intended include infants and young children, pregnant women, and older adults.
This Work Group will consider policy questions related to maternal and pediatric vaccinations and antibody products. The separate adult Work Group will consider policy topics related to vaccination of adults.
Topics under discussion by the Work Group:
Use of RSV vaccine(s) and newly developed immune globulin products under development in infants and young children and pregnant women.
Work Group activities: Consider recommendation options for use of RSV vaccines and antibodies targeting children <18 years-old
Review the epidemiology and burden of RSV disease in children and pregnant women.
Review efficacy, immunogenicity, safety, and cost-effectiveness of RSV vaccine(s) and newly developed immune globulin products in pregnant women and children.
Provide evidence-based recommendation options regarding use of RSV vaccine(s) and newly developed immune globulin products in pregnant women and children.
Identify areas in need of further research for informing potential future vaccine and immune globulin recommendations.
Work Group Lead: Jefferson Jones and Katherine Fleming-Dutra
Work Group Chair: Sarah LongTop of PageRespiratory Syncytial Virus Vaccines – Adult
Work Group Purpose: Respiratory syncytial virus (RSV) is a major cause of lower respiratory illness, particularly among infants and children and among older adults and adults with chronic medical conditions. RSV vaccine development has progressed in the past decade with over 40 candidate vaccines currently in development. Target populations for whom these products are intended include infants and young children, pregnant women, older adults, and adults with chronic medical conditions.
This Work Group will consider policy questions related to adult vaccination. The separate pediatric/maternal Work Group will consider policy topics related to vaccination of infants, young children, and pregnant women.
Topics under discussion by the Work Group:
Pending licensure of products.
Work Group activities:
Consider recommendation options for the use of RSV vaccines in older adults and adults with underlying medical conditions:Review the epidemiology and burden of RSV disease in older adults and adults with underlying medical conditions.
Review efficacy, immunogenicity, safety, and cost-effectiveness of RSV vaccine(s) in older adults and adults with underlying medical conditions.
Provide evidence-based recommendation options regarding use of RSV vaccine(s) in older adults and adults with underlying medical conditions.
Identify areas in need of further research for informing potential future vaccine recommendations.Work Group Lead: Michael Melgar and Amadea Britton
Work Group Chair: Camille KottonTop of Page
							
					
							Last Reviewed:  November 14, 2023						Source: 	National Center for Immunization and Respiratory Diseases
					Facebook
        Twitter
        LinkedIn
        Syndicate homeACIP Home
Meeting Information
Committee Informationplus icon
Role of the ACIP in CDC’s Vaccine Recommendations
Charter
Economics Studies
Committee Membersplus icon
ACIP Membership Roster
Apply for ACIP Membership
Work Groupsplus icon
VaST Reportsplus icon
June 28, 2021
May 24, 2021
May 17, 2021
March 29, 2021
Recommendationsplus icon
Shared Clinical Decision-Making Recommendations
Evidence Based Recommendationsplus icon
About GRADE
Grade Evidence Tables
Evidence to Recommendations Frameworks Vaccines & ImmunizationsImmunization SchedulesVFC ResolutionsVaccine Information Statements (VISs)
  1600 Clifton Road, N.E., Mailstop A27
Atlanta, GA 30329-4027acip@cdc.gov


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue